Abbott Connects Glucose Sensors and Insulin Pumps for Diabetes Management

Abbott Laboratories is advancing diabetes management by connecting its continuous glucose monitoring (CGM) sensors with insulin pumps and smart insulin pens. This integration aims to simplify blood sugar tracking and insulin delivery for individuals living with diabetes who require insulin therapy.

The technology leverages real-time glucose data from CGM sensors. When sensors detect deviations from normal glucose levels, they can automatically adjust insulin dosages through an connected insulin pump or smart pen. The goal is to reduce guesswork in determining insulin needs, potentially leading to improved glycemic control and a less burdensome daily routine.

Abbott's FreeStyle Libre sensors, such as the Libre 2 Plus, are designed to work with automated insulin delivery (AID) systems. In the U.S., the Libre 2 Plus pairs with Tandem's t:slim X2 insulin pump, while in Europe, the Libre 3 sensor is integrated with Ypsomed and CamDiab's mylife™ Loop solution. These integrations can offer fewer sensor changes per month and smartphone-controlled management.

"An AID system is considerably more convenient since you don’t need to constantly check glucose levels and calculate basal insulin dosages," said Dr. Mahmood Kazemi, chief medical officer for Abbott’s diabetes care business. "Because it’s an automatic process, people can feel more confident in spending time focusing on other things in life."

The technology is also extending to connect CGM sensors with smart insulin pens. These pens can record insulin delivery data, assisting users in dosing the correct amount of insulin. Abbott's FreeStyle Libre apps also integrate with connected insulin pens from select manufacturers, adding further convenience to diabetes management.